What it's for (Indications)
- Dothiepin is a tricyclic antidepressant (TCA) primarily indicated for the treatment of moderate to severe depressive illness, especially in patients presenting with prominent features of anxiety and insomnia.
- Its sedative properties can be particularly beneficial for individuals experiencing significant sleep disturbance associated with their depressive state.
- While its primary role is in major depressive disorder, it has also been utilized in the management of generalized anxiety disorder where other agents may not be suitable or effective.
- It is crucial that the diagnosis of depressive illness or anxiety disorder is confirmed by a healthcare professional prior to initiation of dothiepin treatment, and its use should be part of a comprehensive management plan.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of dothiepin must be individualized based on the patient's clinical response, tolerability, and the severity of the condition. Treatment typically begins with a low dose, gradually increasing under medical supervision to achieve optimal therapeutic effect while minimizing adverse reactions. For adults, an initial dose of 25 mg to 50 mg daily, usually administered as a single dose at night due to its sedative effects, is common. The dose can then be increased incrementally, typically by 25 mg every few days, up to a usual maintenance range of 75 mg to 150 mg daily. In some severe cases, doses up to 200 mg daily may be prescribed, but such high doses require careful monitoring due to an increased risk of adverse effects. For elderly patients, lower starting doses (e.g., 25 mg daily) and a slower titration schedule are generally recommended, with a maximum dose typically not exceeding 75 mg daily, due to their increased susceptibility to anticholinergic and cardiovascular side effects. Dosage adjustments may also be necessary in patients with hepatic or renal impairment. |
Safety & Warnings
Common Side Effects
- Dothiepin, being a tricyclic antidepressant, is associated with a range of side effects, primarily due to its anticholinergic, antihistaminic, and alpha-adrenergic blocking properties.
- Common side effects include anticholinergic effects such as dry mouth, blurred vision, constipation, and urinary retention.
- Sedation and drowsiness are frequently reported, especially at the initiation of therapy, and can be therapeutically leveraged for patients with insomnia.
- Cardiovascular effects include orthostatic hypotension, tachycardia, and palpitations; more serious cardiac arrhythmias and QT prolongation can occur, particularly in overdose or in susceptible individuals.
- Other potential side effects include weight gain, dizziness, tremors, sweating, headache, nausea, and sexual dysfunction.
- In elderly patients, there is an increased risk of confusion and cognitive impairment.
- Patients should be advised about these potential effects and to report any troublesome symptoms to their prescribing clinician.
Serious Warnings
- Black Box Warning: Antidepressants, including dothiepin, significantly increase the risk of suicidal thoughts and behavior (suicidality) in children, adolescents, and young adults (up to 24 years of age) with major depressive disorder (MDD) and other psychiatric disorders. This risk was observed in short-term placebo-controlled trials. The risk does not extend to patients over 24 years of age, and there is evidence of a reduced risk with antidepressant use in patients 65 years of age and older. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Dothiepin is not approved for use in pediatric patients. Prescribing dothiepin for any indication in children, adolescents, or young adults must carefully weigh this risk against the clinical need. It is crucial to inform patients and their caregivers about the potential for emergent suicidality and the importance of immediate reporting of any such changes to a healthcare professional.
- Dothiepin carries significant warnings and precautions due to its pharmacological profile.
- It is contraindicated in patients with a recent myocardial infarction, severe heart block, or other serious cardiac arrhythmias due to its cardiotoxicity potential.
- Extreme caution is advised in patients with a history of cardiovascular disease, glaucoma (especially angle-closure), urinary retention, prostatic hypertrophy, or epilepsy.
- There is an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to 25 years of age) receiving antidepressants, particularly during the initial phases of treatment or dose adjustments; close monitoring for clinical worsening and suicidality is paramount.
- Dothiepin has a narrow therapeutic index and is highly toxic in overdose, with cardiotoxicity (e.
- g.
- , arrhythmias, heart block) and central nervous system effects (e.
- g.
- , seizures, coma) being major concerns, making it unsuitable for patients at high risk of self-harm.
- Concomitant use with monoamine oxidase inhibitors (MAOIs) is absolutely contraindicated due to the risk of severe, potentially fatal, reactions.
- Discontinuation should always be gradual to avoid withdrawal symptoms such as nausea, headache, and malaise.
How it Works (Mechanism of Action)
Dothiepin exerts its therapeutic effects primarily as a tricyclic antidepressant (TCA) by modulating neurotransmission in the central nervous system. Its principal mechanism of action involves the potent inhibition of the reuptake of two key monoamine neurotransmitters: serotonin (5-HT) and noradrenaline (norepinephrine) from the synaptic cleft back into the presynaptic neuron. By blocking the reuptake transporters, dothiepin increases the concentration and prolongs the action of these neurotransmitters in the synaptic space, thereby enhancing monoaminergic neurotransmission. While dothiepin exhibits a relatively balanced effect on both serotonin and noradrenaline reuptake, it also possesses significant antagonistic properties at various other receptors. These include histamine H1 receptors (contributing to its prominent sedative effects), muscarinic acetylcholine receptors (responsible for anticholinergic side effects such as dry mouth, blurred vision, and constipation), and alpha-1 adrenergic receptors (contributing to orthostatic hypotension). The sustained increase in synaptic monoamine levels is believed to lead to adaptive changes in receptor sensitivity and neuronal function over time, culminating in its antidepressant and anxiolytic effects.
Commercial Brands (Alternatives)
No other brands found for this formula.